Literature DB >> 16864722

Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.

Samia Mora1, Nader Rifai, Julie E Buring, Paul M Ridker.   

Abstract

BACKGROUND: Current guidelines suggest measuring high-sensitivity C-reactive protein (hs-CRP) as an aid to coronary risk assessment in adults without cardiovascular disease (CVD). Whether other inflammatory biomarkers, such as fibrinogen, add further prognostic information is uncertain. METHODS AND
RESULTS: In a prospective study of 27,742 initially healthy middle-aged women, the associations of baseline immunoassay fibrinogen and hs-CRP measurements with incident CVD were examined over a 10-year follow-up period. Compared with women in the bottom biomarker quintile, age-adjusted hazard ratios (95% confidence intervals [CIs]) for incident CVD for quintiles 2 to 5 of fibrinogen were 1.10 (0.86 to 1.41), 1.30 (1.03 to 1.65), 1.46 (1.16 to 1.85), and 2.43 (1.95 to 3.02); for hs-CRP they were 1.48 (1.06 to 2.05), 1.70 (1.24 to 2.33), 2.20 (1.63 to 2.96), and 3.24 (2.43 to 4.31). After further adjustment for established risk factors, both biomarkers remained associated (P for trend < or = 0.001) with incident CVD (hazard ratio, 1.35; 95% CI, 1.07 to 1.71 for top fibrinogen quintile; and hazard ratio, 1.68; 95% CI, 1.22 to 2.29 for top hs-CRP quintile compared with the bottom quintiles). Further adjustment for the other biomarker resulted in hazard ratios of 1.23 and 1.56 (P for trend = 0.02 and 0.002), respectively. Although fibrinogen correlated positively with hs-CRP (rs = 0.41, P < 0.001), the highest CVD risk was associated with elevated levels of both fibrinogen and hs-CRP: age-adjusted hazard ratio of 3.45 (95% CI, 2.60 to 4.57) for women with fibrinogen > 393 mg/dL and hs-CRP > 3 mg/L compared with < 329 mg/dL and < 1 mg/L, respectively.
CONCLUSIONS: In this cohort of initially healthy women, baseline levels of fibrinogen measured with a high-quality immunoassay provided additive value to hs-CRP and traditional risk factors in predicting incident CVD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864722     DOI: 10.1161/CIRCULATIONAHA.106.634089

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women.

Authors:  David Conen; Paul M Ridker; Brendan M Everett; Usha B Tedrow; Lynda Rose; Nancy R Cook; Julie E Buring; Christine M Albert
Journal:  Eur Heart J       Date:  2010-05-25       Impact factor: 29.983

2.  The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study).

Authors:  Usha B Tedrow; David Conen; Paul M Ridker; Nancy R Cook; Bruce A Koplan; Joann E Manson; Julie E Buring; Christine M Albert
Journal:  J Am Coll Cardiol       Date:  2010-05-25       Impact factor: 24.094

3.  Elevated inflammation in association with alcohol abuse among Blacks but not Whites: results from the MIDUS biomarker study.

Authors:  Yusuf Ransome; Natalie Slopen; Oskar Karlsson; David R Williams
Journal:  J Behav Med       Date:  2017-12-11

4.  Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women.

Authors:  Monik C Jiménez; Kathryn M Rexrode; Gregory Kotler; Brendan M Everett; Robert J Glynn; I-Min Lee; Julie E Buring; Paul M Ridker; Howard D Sesso
Journal:  Am J Hypertens       Date:  2016-05-28       Impact factor: 2.689

5.  Association between high-sensitivity C-reactive protein and hyperuricemia.

Authors:  Tuo Yang; Xiang Ding; Yi-Lun Wang; Chao Zeng; Jie Wei; Hui Li; Yi-Lin Xiong; Shu-Guang Gao; Yu-Sheng Li; Guang-Hua Lei
Journal:  Rheumatol Int       Date:  2016-02-10       Impact factor: 2.631

6.  Uric acid and the development of metabolic syndrome in women and men.

Authors:  Xuemei Sui; Timothy S Church; Rebecca A Meriwether; Felipe Lobelo; Steven N Blair
Journal:  Metabolism       Date:  2008-06       Impact factor: 8.694

7.  Factors associated with low levels of subclinical vascular disease in older adults: multi-ethnic study of atherosclerosis.

Authors:  Erin D Michos; Kenneth M Rice; Moyses Szklo; Gregory L Burke; David S Siscovick; Russell P Tracy; R Graham Barr; Jennifer A Nettleton; Philip Greenland; David R Jacobs; Wendy Post
Journal:  Prev Cardiol       Date:  2009

8.  Effect of prolonged standardized bed rest on cystatin C and other markers of cardiovascular risk.

Authors:  Karin Arinell; Kjeld Christensen; Stéphane Blanc; Anders Larsson; Ole Fröbert
Journal:  BMC Physiol       Date:  2011-12-09

9.  The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study.

Authors:  L-Q Tang; Q-Y Chen; S-S Guo; W-H Chen; C-F Li; L Zhang; X-P Lai; Y He; Y-X-X Xu; D-P Hu; S-H Wen; Y-T Peng; H Liu; L-T Liu; S-M Yan; L Guo; C Zhao; K-J Cao; Q Liu; C-N Qian; J Ma; X Guo; M-S Zeng; H-Q Mai
Journal:  Br J Cancer       Date:  2014-07-22       Impact factor: 7.640

10.  Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study.

Authors:  Jacqueline S Danik; Guillaume Paré; Daniel I Chasman; Robert Y L Zee; David J Kwiatkowski; Alex Parker; Joseph P Miletich; Paul M Ridker
Journal:  Circ Cardiovasc Genet       Date:  2009-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.